AnaBios

AnaBios operates as a specialized provider of human tissue-based research services and platforms, positioning itself at the intersection of human tissue procurement and translational drug discovery. The company's core value proposition is to bridge the 'bench-to-clinic' gap by offering functional assays on viable human tissues, which it argues more accurately predict clinical outcomes than traditional preclinical models. By generating human-relevant data early in the drug development process, AnaBios aims to help its clients de-risk programs, reduce development costs, and advance safer, more effective candidates. It serves pharmaceutical, biotechnology, and academic partners through a combination of tissue/cell supply and proprietary assay services.

Proprietary platforms for procuring, preserving, and conducting functional ex vivo assays on viable human tissues (e.g., heart, DRG, lung). Includes branded assays like CardioPrime (cardiac), Pain Assays (DRG neurons), and Lung Assays, designed to provide human-relevant data at physiological conditions.

AnaBios competes with other human tissue suppliers (e.g., BioIVT, Discovery Life Sciences) and specialized CROs offering ex vivo or primary cell-based testing services. Its differentiation lies in its strong focus on functional, physiologically relevant assays in key therapeutic areas and its proprietary methods for tissue preservation. It also faces competition from emerging technologies like organ-on-a-chip and induced pluripotent stem cell (iPSC)-derived models.